Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shulby, S. A.
Right arrow Articles by Fatatis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shulby, S. A.
Right arrow Articles by Fatatis, A.
[Cancer Research 64, 4693-4698, July 15, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

CX3CR1-Fractalkine Expression Regulates Cellular Mechanisms Involved in Adhesion, Migration, and Survival of Human Prostate Cancer Cells

Shannon A. Shulby1, Nathan G. Dolloff1, Mark E. Stearns2, Olimpia Meucci1 and Alessandro Fatatis1

Departments of 1 Pharmacology and Physiology and 2 Pathology, Drexel University, College of Medicine, Philadelphia, Pennsylvania

Chemokines and their receptors might be involved in the selection of specific organs by metastatic cancer cells. For instance, the CXCR4-SDF-1{alpha} pair regulates adhesion and migration of breast as well as prostate cancer cells to metastatic sites. In this study, we present the first evidence for the expression of CX3CR1—the specific receptor for the chemokine fractalkine—by human prostate cancer cells, whereas human bone marrow endothelial cells and differentiated osteoblasts express fractalkine. The adhesion of prostate cancer cells to human bone marrow endothelial cells in flow conditions is significantly reduced by a neutralizing antibody against fractalkine, and they migrate toward a medium conditioned by osteoblasts, which secrete the soluble form of the chemokine. Finally, fractalkine activates the PI3K/Akt survival pathway in human prostate cancer cells.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
Y. Lu, J. Wang, Y. Xu, A. E. Koch, Z. Cai, X. Chen, D. L. Galson, R. S. Taichman, and J. Zhang
CXCL16 Functions as a Novel Chemotactic Factor for Prostate Cancer Cells In vitro
Mol. Cancer Res., April 1, 2008; 6(4): 546 - 554.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. L. Jamieson, S. Shimizu, J. A. D'Ambrosio, O. Meucci, and A. Fatatis
CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone Tropism
Cancer Res., March 15, 2008; 68(6): 1715 - 1722.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. G. Dolloff, M. R. Russell, N. Loizos, and A. Fatatis
Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the {alpha}-Platelet-Derived Growth Factor Receptor
Cancer Res., January 15, 2007; 67(2): 555 - 562.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel
CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury
Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2056 - 2062.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. S. R. Sastry, A. J. Smith, Y. Karpova, S. R. Datta, and G. Kulik
Diverse Antiapoptotic Signaling Pathways Activated by Vasoactive Intestinal Polypeptide, Epidermal Growth Factor, and Phosphatidylinositol 3-Kinase in Prostate Cancer Cells Converge on BAD
J. Biol. Chem., July 28, 2006; 281(30): 20891 - 20901.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Andre, N. Cabioglu, H. Assi, J. C. Sabourin, S. Delaloge, A. Sahin, K. Broglio, J. P. Spano, C. Combadiere, C. Bucana, et al.
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
Ann. Onc., June 1, 2006; 17(6): 945 - 951.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-W. Kim, R. L. Ferris, and T. L. Whiteside
Chemokine C Receptor 7 Expression and Protection of Circulating CD8+ T Lymphocytes from Apoptosis
Clin. Cancer Res., November 1, 2005; 11(21): 7901 - 7910.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-C. Gevrey, B. M. Isaac, and D. Cox
Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine)
J. Immunol., September 15, 2005; 175(6): 3737 - 3745.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.